View in EDS

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.

Saved in:
Bibliographic Details
Title: Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.
Authors: Ustianowski A; North Manchester General Hospital, Manchester, UK., Levin MJ; University of Colorado School of Medicine, Aurora, CO, USA., De Wit S; Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium., Launay O; Université Paris Cité, Paris, France.; Inserm F-CRIN, I-REIVAC, Paris, France.; Assistance Publique Hôpitaux de Paris, Paris, France., Veekmans B; Anima Research Center, Alken, Belgium., Rampling T; University College London Hospitals NHS Foundation Trust, London, UK., Sullivan JG; Parkway Medical Center, Birmingham, AL, USA., Vishnepolsky M; Kidney Specialists of Southern Nevada, Las Vegas, NV, USA.; DaVita Clinical Research, Las Vegas, NV, USA., Wijewardane P; Baptist Health Center for Clinical Research, Little Rock, AR, USA., Fawadleh Y; Vaccines & Immune Therapies, Clinical Operations, BioPharmaceuticals R&D, AstraZeneca, Mississauga, ON, Canada., Zhang H; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Li M; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Wickramarachchi D; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Sharbaugh A; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA., Beavon R; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Thissen J; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Hirao L; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA., Dzutseva V; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA., Seegobin S; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Streicher K; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA., Kiazand A; Global Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD, USA., Esser MT; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA., Chang LJ; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA., Perez JL; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA., Cohen TS; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA. taylor.cohen@astrazeneca.com.
Source: Clinical drug investigation [Clin Drug Investig] 2026 Feb; Vol. 46 (2), pp. 207-219. Date of Electronic Publication: 2026 Jan 16.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41545648
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ustianowski+A%22">Ustianowski A</searchLink>; North Manchester General Hospital, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Levin+MJ%22">Levin MJ</searchLink>; University of Colorado School of Medicine, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22De+Wit+S%22">De Wit S</searchLink>; Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Launay+O%22">Launay O</searchLink>; Université Paris Cité, Paris, France.; Inserm F-CRIN, I-REIVAC, Paris, France.; Assistance Publique Hôpitaux de Paris, Paris, France.<br /><searchLink fieldCode="AU" term="%22Veekmans+B%22">Veekmans B</searchLink>; Anima Research Center, Alken, Belgium.<br /><searchLink fieldCode="AU" term="%22Rampling+T%22">Rampling T</searchLink>; University College London Hospitals NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Sullivan+JG%22">Sullivan JG</searchLink>; Parkway Medical Center, Birmingham, AL, USA.<br /><searchLink fieldCode="AU" term="%22Vishnepolsky+M%22">Vishnepolsky M</searchLink>; Kidney Specialists of Southern Nevada, Las Vegas, NV, USA.; DaVita Clinical Research, Las Vegas, NV, USA.<br /><searchLink fieldCode="AU" term="%22Wijewardane+P%22">Wijewardane P</searchLink>; Baptist Health Center for Clinical Research, Little Rock, AR, USA.<br /><searchLink fieldCode="AU" term="%22Fawadleh+Y%22">Fawadleh Y</searchLink>; Vaccines & Immune Therapies, Clinical Operations, BioPharmaceuticals R&D, AstraZeneca, Mississauga, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Zhang+H%22">Zhang H</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Li+M%22">Li M</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Wickramarachchi+D%22">Wickramarachchi D</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Sharbaugh+A%22">Sharbaugh A</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Beavon+R%22">Beavon R</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Thissen+J%22">Thissen J</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Hirao+L%22">Hirao L</searchLink>; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.<br /><searchLink fieldCode="AU" term="%22Dzutseva+V%22">Dzutseva V</searchLink>; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.<br /><searchLink fieldCode="AU" term="%22Seegobin+S%22">Seegobin S</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Streicher+K%22">Streicher K</searchLink>; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.<br /><searchLink fieldCode="AU" term="%22Kiazand+A%22">Kiazand A</searchLink>; Global Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Esser+MT%22">Esser MT</searchLink>; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.<br /><searchLink fieldCode="AU" term="%22Chang+LJ%22">Chang LJ</searchLink>; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.<br /><searchLink fieldCode="AU" term="%22Perez+JL%22">Perez JL</searchLink>; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+TS%22">Cohen TS</searchLink>; Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA. taylor.cohen@astrazeneca.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229504817%22">Clinical drug investigation</searchLink> [Clin Drug Investig] 2026 Feb; Vol. 46 (2), pp. 207-219. <i>Date of Electronic Publication: </i>2026 Jan 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>9504817 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1918 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211732563%22">11732563 </searchLink><i>NLM ISO Abbreviation: </i>Clin Drug Investig <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41545648
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40261-025-01515-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 207
    Titles:
      – TitleFull: Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ustianowski A
      – PersonEntity:
          Name:
            NameFull: Levin MJ
      – PersonEntity:
          Name:
            NameFull: De Wit S
      – PersonEntity:
          Name:
            NameFull: Launay O
      – PersonEntity:
          Name:
            NameFull: Veekmans B
      – PersonEntity:
          Name:
            NameFull: Rampling T
      – PersonEntity:
          Name:
            NameFull: Sullivan JG
      – PersonEntity:
          Name:
            NameFull: Vishnepolsky M
      – PersonEntity:
          Name:
            NameFull: Wijewardane P
      – PersonEntity:
          Name:
            NameFull: Fawadleh Y
      – PersonEntity:
          Name:
            NameFull: Zhang H
      – PersonEntity:
          Name:
            NameFull: Li M
      – PersonEntity:
          Name:
            NameFull: Wickramarachchi D
      – PersonEntity:
          Name:
            NameFull: Sharbaugh A
      – PersonEntity:
          Name:
            NameFull: Beavon R
      – PersonEntity:
          Name:
            NameFull: Thissen J
      – PersonEntity:
          Name:
            NameFull: Hirao L
      – PersonEntity:
          Name:
            NameFull: Dzutseva V
      – PersonEntity:
          Name:
            NameFull: Seegobin S
      – PersonEntity:
          Name:
            NameFull: Streicher K
      – PersonEntity:
          Name:
            NameFull: Kiazand A
      – PersonEntity:
          Name:
            NameFull: Esser MT
      – PersonEntity:
          Name:
            NameFull: Chang LJ
      – PersonEntity:
          Name:
            NameFull: Perez JL
      – PersonEntity:
          Name:
            NameFull: Cohen TS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2026 Feb
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1179-1918
          Numbering:
            – Type: volume
              Value: 46
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Clinical drug investigation
              Type: main
ResultId 1